

# Accepted Manuscript

Title: Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: an APEX Trial Substudy

Author: Gerald Chi, C. Michael Gibson, Adrian F. Hernandez, Russell D. Hull, Syed Hassan A. Kazmi, Ahmed Younes, Sargun S. Walia, Anmol Pitliya, Amandeep Singh, Farima Kahe, Arzu Kalayci, Tarek Nafee, Mathieu Kerneis, Fahad AlKhalfan, Alexander T. Cohen, Robert A. Harrington, Samuel Z. Goldhaber

PII: S0002-9343(18)30312-7  
DOI: <https://doi.org/10.1016/j.amjmed.2018.03.031>  
Reference: AJM 14615

To appear in: *The American Journal of Medicine*



Please cite this article as: Gerald Chi, C. Michael Gibson, Adrian F. Hernandez, Russell D. Hull, Syed Hassan A. Kazmi, Ahmed Younes, Sargun S. Walia, Anmol Pitliya, Amandeep Singh, Farima Kahe, Arzu Kalayci, Tarek Nafee, Mathieu Kerneis, Fahad AlKhalfan, Alexander T. Cohen, Robert A. Harrington, Samuel Z. Goldhaber, Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: an APEX Trial Substudy, *The American Journal of Medicine* (2018), <https://doi.org/10.1016/j.amjmed.2018.03.031>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy

Gerald Chi, M.D.<sup>1</sup>; C. Michael Gibson, M.S., M.D.<sup>1</sup>; Adrian F. Hernandez, M.D.<sup>2</sup>; Russell D. Hull, M.D.<sup>3</sup>; Syed Hassan A. Kazmi, M.D.<sup>1</sup>; Ahmed Younes, M.D.<sup>1</sup>; Sargun S. Walia, M.D.<sup>1</sup>; Anmol Pitliya, M.D.<sup>1</sup>; Amandeep Singh, M.D.<sup>1</sup>; Farima Kahe, M.D.<sup>1</sup>; Arzu Kalayci, M.D.<sup>1</sup>; Tarek Nafee, M.D.<sup>1</sup>; Mathieu Kerneis, M.D.<sup>1</sup>; Fahad AlKhalfan, M.D.<sup>1</sup>; Alexander T. Cohen, M.D.<sup>4</sup>; Robert A. Harrington, M.D.<sup>5</sup>; Samuel Z. Goldhaber, M.D.<sup>6</sup>

<sup>1</sup> Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States

<sup>2</sup> Duke University and Duke Clinical Research Institute, Durham, North Carolina, United States

<sup>3</sup> Division of Cardiology, Faculty of Medicine, University of Calgary, Alberta, Canada

<sup>4</sup> Department of Haematological Medicine, Guy's and St Thomas' Hospitals, King's College, London, United Kingdom

<sup>5</sup> Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, United States

<sup>6</sup> Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

*All authors had access to the data and had roles in writing the manuscript.*

**Running Title:** Chi et al. Anemia and Venous Thromboembolism

**Funding:** Portola Pharmaceuticals, Inc.

**Conflict of Interest:** Dr. Chi has received research grant support paid to the Beth Israel Deaconess Medical Center from Portola, Bayer, and Janssen Research. Dr. Gibson reports grant support from Portola Pharmaceuticals during the conduct of the study, and grant support from Johnson & Johnson and Bayer outside the submitted work. Dr. Hernandez reports receipt of grant support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Luitpold, Merck, and Novartis; and personal fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Luitpold, and Novartis outside the submitted work. Dr. Hull reports grant support from Portola Pharmaceuticals during the conduct of the study, and grant support and personal fees from Leo Pharma outside the submitted work. Dr. Cohen reports grant support, personal fees, and non-financial support from Portola Pharmaceuticals during the conduct of the study; grant support, personal fees, and non-financial support from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Janssen, and Bayer Pharmaceuticals, personal fees from Boehringer Ingelheim and Sanofi, and personal fees and non-financial support from Johnson & Johnson and Aspen Pharmaceuticals outside the submitted work. Dr. Harrington reports grant support from Portola Pharma during the conduct of the study; grant support from CSL Behring, AstraZeneca, GlaxoSmithKline, Regado, and Sanofi Aventis, grant support and personal fees from Merck and The Medicines Company, personal fees from Amgen, Gilead Sciences, MyoKardia, and WebMD, and other support from Scanadu, SignalPath, Element Science, Vida Health, and Adverse Events outside the submitted work. Dr. Goldhaber has provided consulting for Boehringer Ingelheim, Bayer, Portola, Daiichi-Sankyo, Janssen, BiO2 Medical, EKOS/ BTG, BMS, and Zafgen. All other authors declare no conflict of interest.

**Word Count:** 292 (abstract); 1,992 (text)

### **Address for Correspondence:**

Gerald Chi, M.D.

Division of Cardiovascular Medicine

Department of Medicine

Beth Israel Deaconess Medical Center

Harvard Medical School

930 Commonwealth Avenue #3

Boston, Massachusetts 02215

United States

Telephone: (617) 975-9952

Fax: (617) 975-9955

Email: geraldccchi@gmail.com

Download English Version:

<https://daneshyari.com/en/article/8944096>

Download Persian Version:

<https://daneshyari.com/article/8944096>

[Daneshyari.com](https://daneshyari.com)